ERBB2 and neoplasm: We showed that HER2 amplification is present in a clinically relevant proportion of tumors and in a variety of tumor types and that HER2-targeted therapy may confer clinical benefit, with increased survival in patients with tumor types other than those for which HER2 inhibitors are approved.